“ These results further demonstrate that high-risk PCI procedures supported by Impella employing contemporary best practices are safe and effective, providing a treatment option for patients who have ...
According to the World Health Organization, diseases of the circulatory system, including heart disease such as heart attacks, are still among the most common causes of death worldwide. Recovering the ...
DANVERS, Mass.--(BUSINESS WIRE)--The United States Food and Drug Administration (FDA) has granted breakthrough device designation to Abiomed’s (NASDAQ: ABMD) Impella ECP expandable percutaneous heart ...
DANVERS, Mass. – October 24, 2024 – Novel data on the benefits of Impella ® heart pump technology in high-risk percutaneous coronary intervention (PCI) and cardiogenic shock will be presented during ...
In the latest observational study to address Impella’s role—this time using a large US claims database—patients who received the percutaneous left ventricular assist device (PVAD) during high-risk PCI ...
Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...
DANVERS, Mass. – Nov. 27, 2023 – Abiomed, part of Johnson & Johnson MedTech[1], announces the first patient in the world has been enrolled in the landmark RECOVER IV randomized controlled trial (RCT).
Adding another layer to Abiomed’s challenging last few months connected to its Impella heart pumps, FDA has updated the device’s Class I recall regarding a potential conflict in patients with ...
Johnson & Johnson has instructed users to remove certain Impella CP sets with SmartAssist from where they are used or sold. According to FDA, impacted lots include 613525, 644314, 645428, 644591, ...
Abiomed has reported eight instances of major bleeding, with three ‘contested’ patient deaths related to a leakage issue with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results